{
    "clinical_study": {
        "@rank": "1484", 
        "arm_group": [
            {
                "arm_group_label": "Methylphenidate", 
                "arm_group_type": "Experimental", 
                "description": "Intervention: An escalating dose of methylphenidate taken by mouth: 20mg for 2 weeks, 40mg for 2 weeks, 60mg for 2 weeks. All doses divided twice/day.\nOther name: Ritalin"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo pill, bid for 6 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Methylphenidate is an amphetamine-like psychomotor stimulant drug currently approved for the\n      treatment of attention-deficit hyperactivity disorder (ADHD), postural orthostasis\n      tachycardia syndrome and narcolepsy. It is also often prescribed off label to people with MS\n      to improve fatigue. It is proposed that methylphenidate may also improve imbalance and\n      walking deficits in MS by improving concentration and central integration, one of the\n      primary mechanisms thought to underlie imbalance and walking deficits in MS."
        }, 
        "brief_title": "Methylphenidate to Improve Balance and Walking in MS", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The proposed pilot study will examine the effects of methylphenidate on imbalance and\n      walking in 24 subjects with MS and imbalance.  The subjects will be randomly assigned to\n      receive either an escalating does of methylphenidate, 20mg, 40mg or 60mg, divided into two\n      doses each day, or matched placebo for 2 weeks at each dose.  If a subject does not tolerate\n      dose escalation they will be instructed to discontinue use of the drug. The maximum safely\n      tolerated dose for each subject will be noted. Changes from baseline in subject's walking\n      speed, balance, vestibular function, cognitive function, and fatigue will be assessed at\n      each dose."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 20-59\n\n          -  Able to walk at least 100m without an aide or with unilateral assistance\n\n          -  Poor static balance, specifically prolonged APR latencies (\u2265 1 standard deviation\n             (SD) > mean for healthy people in this age range), OR\n\n          -  Reduced balance-related activity (ABC scores \u2264 85%)\n\n          -  Walking difficulties, specifically T25FW > 6 seconds, OR reduced self perceived\n             walking (MSWS-12 scores \u2265 50/60)\n\n        Exclusion Criteria:\n\n          -  Currently taking methylphenidate, modafinil, armodafinil, or dalfampridine (any\n             within the last 2 weeks)\n\n          -  Cause(s) of imbalance other than MS\n\n          -  Systolic pressure consistently greater than 150 mm Hg or diastolic pressure\n             consistently greater than 90 mm Hg\n\n          -  Contraindications to methylphenidate (Anxiety, tension, agitation, thyrotoxicosis,\n             tachyarrhythmias, severe angina pectoris or glaucoma, hypersensitivity to\n             methylphenidate, motor tics or a family history or diagnosis of Tourette's syndrome,\n             seizures, severe or poorly controlled hypertension, treatment with monoamine oxidase\n             inhibitors currently or within the last 14 days, current use of guanethidine,\n             pressors, coumarin anticoagulants, anticonvulsants, phenylbutazone, or tricyclic\n             antidepressants, history of drug abuse or alcoholism)\n\n          -  Pregnancy or breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "59 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01896700", 
            "org_study_id": "3055"
        }, 
        "intervention": [
            {
                "arm_group_label": "Methylphenidate", 
                "description": "Escalating dose of methylphenidate, 20mg, 40mg, 60mg/day, for 2 weeks each", 
                "intervention_name": "Methylphenidate (Ritalin)", 
                "intervention_type": "Drug", 
                "other_name": "Ritalin"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Escalating matched dose of placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Methylphenidate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Multiple sclerosis", 
            "postural balance", 
            "walking"
        ], 
        "lastchanged_date": "January 13, 2014", 
        "location": {
            "contact": {
                "email": "Ashley.Downs@va.gov", 
                "last_name": "Ashley Downs, B.S.", 
                "phone": "503-220-8262", 
                "phone_ext": "52016"
            }, 
            "contact_backup": {
                "email": "teem@ohsu.edu", 
                "last_name": "Melissa Tee, M.A.", 
                "phone": "503-494-3549"
            }, 
            "facility": {
                "address": {
                    "city": "Portland", 
                    "country": "United States", 
                    "state": "Oregon", 
                    "zip": "97239"
                }, 
                "name": "Portland VA Medical Center"
            }, 
            "investigator": {
                "last_name": "Michelle H Cameron, MD, PT", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Methylphenidate to Improve Balance and Walking in MS", 
        "overall_contact": {
            "email": "Ashley.Downs@va.gov", 
            "last_name": "Ashley Downs, BS", 
            "phone": "503-220-8262", 
            "phone_ext": "52016"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome of this study will be the difference between mean change in TUG time between methylphenidate and placebo treated subjects at each dose.  Changes in TUG times will be calculated by comparing the TUG time at each time point (i.e. dose) after intervention (T+2weeks, T+4weeks and T+6weeks) with the baseline TUG time.  Mean changes at each time point will be compared for active and placebo treated subjects using t-tests.", 
            "measure": "Timed Up and Go time (TUG time)", 
            "safety_issue": "No", 
            "time_frame": "Up to 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01896700"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Oregon Health and Science University", 
            "investigator_full_name": "Michelle Cameron", 
            "investigator_title": "Neurologist, Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Mean changes in APR latency at each time point will be compared for active and placebo treated subjects using t-tests.", 
                "measure": "Automatic Postural Response (APR) Latency (in sec)", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 weeks"
            }, 
            {
                "description": "Mean changes in Timed 25 Foot Walk (T25FW) at each time point will be compared for active and placebo treated subjects using t-tests.", 
                "measure": "Timed 25 Foot Walk (T25FW in secs)", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 weeks"
            }, 
            {
                "description": "Mean changes in the score attained on the Pittsburgh Sleep Quality Assessment Questionnaire at each time point will be compared for active and placebo treated subjects using t-tests.", 
                "measure": "Pittsburgh Sleep Quality Assessment Questionnaire score", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 weeks"
            }, 
            {
                "description": "Mean changes in the score attached on the Modified Fatigue Index Scale at each time point will be compared for active and placebo treated subjects using t-tests.", 
                "measure": "Modified Fatigue Index Scale score", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 weeks"
            }, 
            {
                "description": "Mean changes in saccade latency and peak velocity at each time point will be compared for active and placebo treated subjects using t-tests.", 
                "measure": "Vestibular-Ocular Reflex time (in secs)", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 weeks"
            }
        ], 
        "source": "Oregon Health and Science University", 
        "sponsors": {
            "collaborator": {
                "agency": "Portland VA Medical Center", 
                "agency_class": "U.S. Fed"
            }, 
            "lead_sponsor": {
                "agency": "Oregon Health and Science University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}